New Statistical Method Provides Timely Comparative Effectiveness Research

Published Sep 17, 2012
Boston, MA, USA - Health care companies face increased pressure to compare the effectiveness of new treatments as early as possible. A study published in Value in Health reports on a novel statistical method that can be used to compare approved treatments even early in the product’s life cycle. Researchers at Analysis Group Inc., a health economic consultancy in Boston, MA, and at Shire Development LLC, in Wayne, PA, illustrate in their report how the method works. In their article, “Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research,” the authors discuss the application of this method in the areas of oncology, dermatology, diabetes, and attention-deficit hyperactivity disorder. While randomized head-to-head trials are the gold standard for comparing treatments, the new approach can provide indirect comparative evidence when such trials are not available. “The key is to fully leverage clinical trial data from pharmaceutical or device manufacturers,” says James Signorovitch, PhD, of Analysis Group, lead author of the article. Generally, clinical trials used to gain regulatory approval for new drugs or devices do not include comparisons of competing products. The study’s authors address this by using detailed patient data from the new product’s trials to match populations studied in published trials of competing products. Treatment outcomes are then evaluated between comparable populations. The article was sponsored by Shire Development LLC. Assistance with the writing of this press release was provided by Shire Development LLC.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×